Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S. Perry, Hon BSc, DVM, Ph.D., to its board of directors.

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors

Pasadena, CA | Posted on December 19th, 2011

Dr. Perry brings over 25 years of successful biotechnology and pharmaceutical management and research and development experience, as well as healthcare investing expertise to Arrowhead. He has a proven track record in research and development innovation, with emphasis on product development and approval, strategic portfolio management, integration of company mergers and acquisitions, business development, and driving shareholder value. Dr. Perry is currently a Venture Partner at Bay City Capital, a life science focused investment fund that manages seven funds, representing approximately $1.6 billion in capital. He is also President and Chief Medical Officer of Poniard Pharmaceuticals (PARD: NASDAQ).

"Mike's knowledge and experience in drug development will be instrumental as we progress our lead candidates through clinical development," said Dr. Christopher Anzalone, President and Chief Executive Officer. "In addition, his expertise in strategic business development transactions and product assessment will be important as we continue to execute on our partnership and broader business strategies."

Dr. Perry has filed over 50 investigational new drug applications, and over 30 new drug applications and biologic license applications, for a number of companies across the globe. His previous roles include Chief Development Officer of VIA Pharmaceuticals and Founder and Chief Executive Officer of Extropy Pharmaceuticals. He was also Chief Executive Officer of Pharsight, SyStemix and Genetic Therapy, serving as a director on each of the companies' boards. Prior to these positions, Dr. Perry was Global Head of Research and Development for Baxter BioScience, Vice President of Novartis Pharma, and Vice President of Syntex Corporation. He currently serves as a member of the board of directors of AmpliPhi Biosciences Corporation (APHB.PK).

"I look forward to serving on Arrowhead's Board of Directors," said Perry. "The company has emerged as a leader in the development of RNAi therapeutics with access to a broad suite of intellectual property and novel delivery solutions. I look forward to contributing to Arrowhead's continuing future success as an independent director."

Dr. Perry holds an Honors BSc in Engineering/Physics from the University of Guelph, a DVM from the Ontario Veterinary College, and a Ph.D. in Biomedical Pharmacology from the University of Guelph. He is a Fellow of the Royal College of Veterinary Surgeons and a graduate of the Executive International Management Program at Harvard Business School.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The company's lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and Adipotide™, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic Polyconjugate™ (DPC), Liposomal Nanoparticle (LNP), and RONDEL™ delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies. For more information, please visit
www.arrowheadresearch.com.


Safe Harbor Statement Under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Investor Relations Contact:
The Trout Group, LLC
Marcy Nanus
646-378-2927

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Renishaw receives Queen's Award for spectroscopy developments November 25th, 2014

JPK reports on the use of AFM and the CellHesion module to study plant cells at the University of Queensland November 25th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Nanomedicine

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014

ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014

An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014

Announcements

Renishaw receives Queen's Award for spectroscopy developments November 25th, 2014

JPK reports on the use of AFM and the CellHesion module to study plant cells at the University of Queensland November 25th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Mining entrepreneur Julian Malnic Joins Deep Space Industries’ Board: Deep Space Industries welcomes a prolific mining entrepreneur and accomplished company builder, Julian Malnic, to its Board of Directors November 14th, 2014

SEMATECH Names Ronald Goldblatt Permanent Chief Executive Officer November 7th, 2014

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

VDMA photonics steering committee with new members stronger than ever October 14th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE